



July 13, 2013

Dear kmira zahra,

Thank you for choosing NPG Language Editing. I enjoyed reading your case report on the development of severe hemorrhagic colitis following dasatinib use. Overall, this was a nicely structured paper, and the results were very clearly demonstrated. The thoughts were presented logically and carefully, although the exact wording was edited to improve the flow of the paper. The following suggestions highlight the most significant problem areas of this manuscript:

- 1) The use of relative pronouns (that, which, where, etc.) to introduce a relative clause was often edited throughout the paper. In general, “that” is used restrictively to narrow a class or identify a particular item being discussed. Because “that” introduces a restrictive clause, commas are not used before or after the “that” clause. In contrast, “which” or “where” are often used nonrestrictively. In this case, commas around the “which” or “where” clause need to be used, whereas commas are not required when using “that”. For example, “the characteristics of our case suggest that dasatinib engenders hemorrhagic colitis which usually stops by discontinuation of the drug” was changed to “the characteristics of our patient suggest that dasatinib treatment can lead to hemorrhagic colitis, which typically resolves after discontinuation of the drug.”
- 2) Other sentences were edited to improve sentence structure, clarity, and flow. For example, “gastrointestinal bleeding may occur in up to 7% of patients using dasatinib. Dasatinib-related severe acute colitis was rarely reported” was changed to “gastrointestinal bleeding may occur in up to 7% of patients using dasatinib, although severe dasatinib-related acute colitis has rarely been reported.”
- 3) Finally, some edits were made to change awkward or potentially unclear phrasing. For example, “the colitis induced by dasatinib might not be attributed simply to the tyrosine kinase inhibition because she did not have particular GI symptoms during imatinib therapy” was changed to “the colitis induced by dasatinib may not be attributed simply to tyrosine kinase inhibition because our patient did not experience similar GI symptoms during imatinib therapy.”

Please review the comments in the file and all our changes carefully for more detailed feedback and suggestions, as well as to ensure that the final version of the manuscript is fully accurate.

Thank you again for using our editing services; we wish you the best of luck with your submission.

Best Regards,

Kate S.
Senior Editor
NPG Language Editing